BRAF and neoplasm: Since the last two decades, certain histology-based prediction models that rely on hand-crafted clinico-pathologic feature extraction—such as age < 50, female sex, right sided location, size >= 60 mm, BRAF mutation, tumor infiltrating lymphocytes (TILs), a peritumoral lymphocytic reaction, mucinous morphology and increased stromal plasma cells—have reported encouraging performance but has not been sufficient to supersede universal testing for MSI/dMMR [9].